非典型溶血性尿毒症综合征患者肾移植后依库珠单抗治疗的成本效益分析
该研究采用决策分析模型和马尔可夫链分析,比较了透析、肾移植、复发时使用依库珠单抗、诱导期12个月预防及终身预防五种策略的成本效益。结果显示肾移植优于透析,复发时使用依库珠单抗的增量成本效果比为每QALY 18 748欧元,且优于诱导期和终身预防策略。
要点
- 肾移植治疗aHUS所致ESRD的成本效益优于透析。
- 复发时使用依库珠单抗较无依库珠单抗增加QALYs,ICER为18 748欧元/QALY。
- 诱导期或终身依库珠单抗预防不增加QALYs且成本更高。
核心结论
- 对于aHUS所致ESRD,肾移植比透析更具成本效益。
- 加用依库珠单抗可显著增加QALYs。
- 复发时使用依库珠单抗比诱导期或终身预防更可接受。
研究设计与样本
- 成本效益分析,采用决策分析方法和马尔可夫链分析。
- 假设所有患者接受活体供肾,移植后第一年复发概率为28.4%。
主要发现
- 无依库珠单抗的肾移植获得8.34 QALYs,成本402 412欧元,为成本最低方案。
- 透析成本更高且QALYs更少。
- 复发时使用依库珠单抗获得9.55 QALYs,成本425 097欧元,ICER为18 748欧元/QALY。
- 诱导期和终身依库珠单抗方案QALYs更少且成本更高。
临床怎么用
- 对于aHUS所致ESRD患者,优先考虑肾移植而非透析。
- 在肾移植后,采用复发时使用依库珠单抗策略可能更具成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Kidney transplantation in patients with atypical haemolytic uraemic syndrome (aHUS) is frequently complicated by recurrence of aHUS, often resulting in graft loss. Eculizumab prophylaxis prevents recurrence, improving graft survival. An alternative treatment strategy has been proposed where eculizumab is administered upon recurrence. We combined available evidence and performed a cost-effectiveness analysis of these competing strategies. METHODS: A cost-effectiveness analysis using a decision analytical approach with Markov chain analyses was used to compare alternatives for aHUS patients with end-stage renal disease (ESRD): (i) dialysis treatment, (ii) kidney transplantation, (iii) kidney transplantation with eculizumab therapy upon recurrence of aHUS, (iv) kidney transplantation with eculizumab induction consisting of 12 months of prophylaxis and (v) kidney transplantation with lifelong eculizumab prophylaxis. We assumed that all patients received a graft from a living donor and that recurrence probability was 28.4% within the first year of transplantation. RESULTS: At 8.34 quality-adjusted life years (QALYs) gained and a cost of €402 412, kidney transplantation without eculizumab was the least costly alternative. By comparison, dialysis was more costly and resulted in fewer QALYs gained. Eculizumab upon recurrence resulted in 9.55 QALYs gained at a cost of €425 097. The incremental cost-effectiveness ratio (ICER) was €18 748 per QALY. Both eculizumab induction and lifelong eculizumab were inferior to eculizumab upon recurrence, as both resulted in fewer QALYs gained and higher costs. CONCLUSIONS: Kidney transplantation is more cost effective than dialysis to treat ESRD due to aHUS. Adding eculizumab treatment results in a substantial gain in QALYs. When compared with eculizumab upon recurrence, neither eculizumab induction nor lifelong eculizumab prophylaxis resulted in more QALYs, but did yield far higher costs. Therefore, eculizumab upon recurrence of aHUS is more acceptable.
引用
- van den Brand JA, Verhave JC, Adang EM, et al. Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome. Nephrol Dial Transplant. 2017. PMID: 28391343. doi:10.1093/ndt/gfw353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。